Citi Pharma Limited (PSX:CPHL)
Pakistan
· Delayed Price · Currency is PKR 70.14
-7.79 (-10.00%)
At close: Mar 9, 2026
Citi Pharma Cash Flow Statement
Financials in millions PKR. Fiscal year is July - June.
Millions PKR. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2016 |
| Net Income | 1,042 | 892.04 | 833.46 | 657.98 | 653.69 | 351.77 | Upgrade
|
| Depreciation & Amortization | 208.59 | 168.09 | 138.22 | 90.59 | 76.83 | 65.69 | Upgrade
|
| Loss (Gain) From Sale of Investments | 327.6 | 327.7 | -29.28 | 35.12 | 4.48 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 2.2 | 2.2 | 4.78 | - | - | - | Upgrade
|
| Other Operating Activities | -300.74 | -404.11 | 55.33 | -26.27 | 136.33 | 49.47 | Upgrade
|
| Change in Accounts Receivable | -1,071 | -885.74 | -282.69 | -480.58 | -957.02 | -145.08 | Upgrade
|
| Change in Inventory | -1.09 | -726.33 | -594.39 | -917.35 | -913.44 | 113.53 | Upgrade
|
| Change in Accounts Payable | -1,105 | 227.32 | 1,359 | 260.08 | 782.19 | -188.6 | Upgrade
|
| Change in Other Net Operating Assets | -46.23 | 78.13 | -146.79 | 51.42 | -106.03 | -22.38 | Upgrade
|
| Operating Cash Flow | -943.91 | -320.7 | 1,338 | -329 | -322.97 | 224.4 | Upgrade
|
| Operating Cash Flow Growth | - | - | - | - | - | 138.49% | Upgrade
|
| Capital Expenditures | -82.81 | -150.06 | -568.2 | -954.47 | -600.46 | -276.7 | Upgrade
|
| Investment in Securities | 0.45 | 42.31 | 52.83 | 179.77 | -312.12 | - | Upgrade
|
| Other Investing Activities | 0.77 | -5.23 | 3.43 | -6.13 | -8.91 | - | Upgrade
|
| Investing Cash Flow | -81.59 | -112.98 | -511.94 | -780.83 | -921.48 | -276.7 | Upgrade
|
| Short-Term Debt Issued | - | 1,470 | - | 1,246 | 509.37 | 122.8 | Upgrade
|
| Long-Term Debt Issued | - | - | - | - | 300 | 146.95 | Upgrade
|
| Total Debt Issued | 3,842 | 1,470 | - | 1,246 | 809.37 | 269.74 | Upgrade
|
| Short-Term Debt Repaid | - | -37.73 | -331.54 | - | - | -5 | Upgrade
|
| Long-Term Debt Repaid | - | -45.15 | -56.17 | -383.24 | -148.3 | -74.99 | Upgrade
|
| Total Debt Repaid | -73.74 | -82.89 | -387.7 | -383.24 | -148.3 | -79.99 | Upgrade
|
| Net Debt Issued (Repaid) | 3,769 | 1,387 | -387.7 | 863.24 | 661.07 | 189.75 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | - | 2,326 | Upgrade
|
| Common Dividends Paid | -796.6 | -739.82 | -571.15 | - | -311.54 | - | Upgrade
|
| Other Financing Activities | -0.58 | -0.58 | - | - | -521.38 | 521.38 | Upgrade
|
| Financing Cash Flow | 2,971 | 646.82 | -958.86 | 863.24 | -171.85 | 3,037 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | - | - | - | - | - | -0 | Upgrade
|
| Net Cash Flow | 1,946 | 213.14 | -133.2 | -246.58 | -1,416 | 2,985 | Upgrade
|
| Free Cash Flow | -1,027 | -470.77 | 769.4 | -1,283 | -923.43 | -52.3 | Upgrade
|
| Free Cash Flow Margin | -7.28% | -3.58% | 6.20% | -10.35% | -9.44% | -0.90% | Upgrade
|
| Free Cash Flow Per Share | -4.49 | -2.06 | 3.37 | -5.62 | -4.07 | -0.28 | Upgrade
|
| Cash Interest Paid | 384.96 | 356.83 | 289.99 | 329.3 | 58.73 | 39.22 | Upgrade
|
| Cash Income Tax Paid | 678.79 | 574 | 461.13 | 367.92 | 309.61 | 126.46 | Upgrade
|
| Levered Free Cash Flow | -1,065 | -567.3 | 446.95 | -1,324 | -1,497 | 759.74 | Upgrade
|
| Unlevered Free Cash Flow | -788.29 | -368.76 | 631.59 | -1,240 | -1,461 | 782.08 | Upgrade
|
| Change in Working Capital | -2,223 | -1,307 | 335.09 | -1,086 | -1,194 | -242.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.